I koma frå fengselet

Tidsskrift for den Norske Laegeforening

Volumn 130, Issue 3, 2010, Pages 284-285

  Sæverud, Håvard A ^a   Gerlyng, Per ^a  

^a Medisinsk klinikk   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; COMA; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; HUMAN; MALE; METABOLIC SYNDROME X; PRISONER; PSYCHOSIS; RISK FACTOR;

ADULT; ANTIPSYCHOTIC AGENTS; COMA; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; HUMANS; MALE; METABOLIC SYNDROME X; PRISONERS; PSYCHOTIC DISORDERS; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 77649200074     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.09.0698     Document Type: Article

References (11)

1. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
2. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiat 2006; 51: 480-91.
3. Birkenaes AB, Birkeland KI, Engh JA et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008; 28: 132-7.
4. Ader M, Kim SP, Catalano KJ et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005; 54: 862-71.
5. Koller EA, Cross JT, Doraiswamy PM et al. Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's Med-Watch surveillance system and published reports. Pharmacotherapy 2003; 23: 1123-30.
6. Goldstein LE, Sporn J, Brown S et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40: 438-43.
7. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002; 22: 841-52.
8. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (suppl 1): 1-93.
9. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiat 2006; 51: 492-501.
10. American Diabetes Association. American Psychiatric Association. American Association of Clinical Endocrinologists. North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601.
11. Andreassen OA, Bentsen H. Metabolske og kardiovaskulære bivirkninger av moderne antipsykotika. Tidsskr Nor Lægeforen 2004; 124: 181-2.